<DOC>
	<DOC>NCT01763788</DOC>
	<brief_summary>The purpose of the Phase 1b portion of the study is to investigate how the body tolerates necitumumab, in combination with gemcitabine and cisplatin chemotherapy as first line treatment in participants with Stage IV squamous NSCLC and to determine the recommended dose for the subsequent Phase 2 portion of the study. The purpose of the Phase 2 portion of the study is to evaluate the efficacy of necitumumab in combination with gemcitabine and cisplatin chemotherapy in participants with Stage IV squamous NSCLC in a first-line setting.</brief_summary>
	<brief_title>A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Squamous NonSmall Cell Lung Cancer Disease Clinical Stage IV Measurable or nonmeasurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1 No prior chemotherapy regimen, surgery and chest radiotherapy Adequate organ function Estimated life expectancy of at least 12 weeks Has undergone major surgery within 28 days prior to enrollment or have planned major surgery, subcutaneous venous access device placement within 7 days prior to enrollment Has undergone any prior radiation therapy, except for Gamma Knife radiation and palliative radiation treatment at least 14 days have elapsed from last radiation treatment prior to enrollment Has brain metastases that are symptomatic or require surgery, medication and radiotherapy except Gamma Knife Has superior vena cava syndrome Has clinically relevant coronary artery disease or uncontrolled congestive heart failure Has uncontrolled hypertension Has diabetes requiring insulin Has an angina or has experienced myocardial infarction within 6 months prior to enrollment Has an Acquired Immunodeficiency Syndrome (AIDS)related illness Has evidence of or test positive test results for hepatitis B, or hepatitis C virus antibodies Has a known allergy and history of hypersensitivity reaction Has significant thirdspace fluid retention Has history of interstitial pneumonitis Has an ongoing or active infection Has a history of significant neurological or psychiatric disorders Has a Grade 2 peripheral neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>